BackgroundHepatitis B virus (HBV) is the major cause of acute and chronic hepatitis, leading to progressive development of necroinflammatory changes in the liver, which can result in cirrhosis and hepatocellular carcinoma. Although the development of an effective vaccine to prevent HBV infection has shown promising results and should lead to its eventual eradication, antiviral chemotherapy remains the only effective method to prevent the progression of the disease in chronic carriers. Therefore, the development of new antiretroviral agents active against HBV is needed. HepG2 cells have an epithelial morphology and are thought to be a very useful model to study HBV virus replication via transfection. Cells are also used for cancer and apoptosis studies (in particular signalling pathway studies).

Thank you for contacting us. The exact protocol is proprietary for ab14659, but the cytoplasmic membrane is first lysed in the hypotonic buffer to harverst the nuclei. Then the proteins from the nuclei are extracted with a lysis buffer. The sample...

I am sorry about the issues you have been having with ab108447 in western blot. The antibody is covered under our Abpromise for six months and is guaranteed to work in western blot on human. If we cannot resolve...

After further investigation, I found that the WB application was added by error which was removed a week after. The reason for removal was, non availability of tested data to prove the suitability. However this do...